Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Income (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Non Operating Income for 6 consecutive years, with -$501000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 531.9% to -$501000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$79000.0 through Dec 2025, down 119.32% year-over-year, with the annual reading at $4000.0 for FY2025, 98.94% down from the prior year.
  • Non Operating Income hit -$501000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $194000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.3 million in Q2 2021 to a low of -$501000.0 in Q4 2025.
  • Historically, Non Operating Income has averaged $77900.0 across 5 years, with a median of $101000.0 in 2024.
  • Biggest five-year swings in Non Operating Income: surged 13900.0% in 2024 and later plummeted 531.9% in 2025.
  • Year by year, Non Operating Income stood at -$108000.0 in 2021, then skyrocketed by 265.74% to $179000.0 in 2022, then surged by 67.6% to $300000.0 in 2023, then tumbled by 61.33% to $116000.0 in 2024, then tumbled by 531.9% to -$501000.0 in 2025.
  • Business Quant data shows Non Operating Income for IMDX at -$501000.0 in Q4 2025, $194000.0 in Q3 2025, and $100000.0 in Q2 2025.